Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID).
CVID is characterized by reduced serum levels of all switched immunoglobulin isotypes (IgG, IgA, IgE) predisposing patients to recurrent infections of their respiratory and gastrointestinal tract. Correspondingly, most CVID patients exhibit a severely decreased proportion of class switched memory B cells (CD19+CD27+IgD-IgM-IgG+ or IgA+) in their peripheral blood (CVID type I). We previously identified a subgroup of CVID patients showing a significantly reduced expression of CD86 and CD137 following activation in vitro of PBMC or purified B cells (CD19+) with anti-IgM plus IL-2. Here we extend our previous studies by asking whether highly purified, cell-sorted naive B cells show already an expression defect of B cell surface molecules relevant in activation (CD39, CD69), differentiation (CD24, CD27, CD38) or T-B interaction (CD25, CD70, CD86). We stimulated cell-sorted, naive B cells (CD19+CD27-IgM+IgDhighIgG-IgA-) from 10 CVID patients and 10 healthy controls for 4 days with anti-IgM plus IL-2 in the absence or presence of autologous CD4+ T cells and measured the expression of the referred surface molecules. Based on reduced or normal numbers of switched memory B cells the CVID patients had previously been classified into eight type I patients and two type II patients, respectively. Interestingly, only the molecules CD25, CD70 and CD86, all relevant in cognate T-B interaction, showed a significantly lower expression in naive B cells from CVID patients compared to controls. While coculture with autologous CD4+ T cells normalized the CD25 expression, CD70 and CD86 expression remained subnormal, notably in the eight CVID patients of type I. These findings strongly suggest an intrinsic signalling or expression defect for CD70/CD86 at the level of naive B cells in type I CVID patients.
Groth
C
C
Division of Rheumatology and Clinical Immunology, Department of Medicine, University Hospital Freiburg, Germany.
Drager
R
R
Warnatz
K
K
Wolff-Vorbeck
G
G
Schmidt
S
S
Eibel
H
H
Schlesier
M
M
Peter
H-H
HH
D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000276:immunology; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D000955:Antigens, T-Independent / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000378:metabolism*; D051940:B7-2 Antigen; D053282:CD27 Ligand; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D017074:Common Variable Immunodeficiency / Q000235:genetics / Q000276:immunology*; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D007156:Immunologic Memory; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology; D008213:Lymphocyte Activation; D008211:Lymphocyte Cooperation; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D008565:Membrane Proteins / Q000096:biosynthesis / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D008875:Middle Aged; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis / Q000172:deficiency / Q000235:genetics
D000888:Antibodies, Anti-Idiotypic; D000942:Antigens, Bacterial; D015703:Antigens, CD; D000955:Antigens, T-Independent; D051940:B7-2 Antigen; D053282:CD27 Ligand; C505771:CD70 protein, human; C497964:CD86 protein, human; D007075:Immunoglobulin M; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D011947:Receptors, Antigen, B-Cell; D015375:Receptors, Interleukin-2; C044203:anti-IgM